Article
MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study.
AIDS (London, England) - 18 Jun 2004
Katlama Christine, Ghosn Jade, Tubiana Roland, Wirden Marc, Valantin Marc-Antoine, Harmenberg Johan, Mårdh Göran, Oberg Bo, Calvez Vincent
Abstract excerpt
BACKGROUND: Drug resistance is an increasing problem in the treatment of HIV infection. MIV-310 (alovudine), a nucleoside reverse transcriptase inhibitor, potently inhibits the replication of highly mutated strains of HIV in vitro. We examined the efficacy of MIV-310 in highly pretreated patients. METHODS: In a phase II pilot study, 15 patients failing a current antiretroviral therapy with at least two...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.